XML 20 R10.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue from Contracts with Customers
 3 Months Ended
Mar. 31, 2021
Revenue from Contract with Customer [Abstract]  
Revenue from Contracts with Customers Revenue from Contracts with Customers
The following table summarizes revenue by revenue source as follows:
Three Months Ended
March 31,
Major Products/Service Lines (in thousands)20212020
    Product revenue, net(1)

$87,319 $90,213 
    License and royalty revenues5,190 491 
Total revenues$92,509 $90,704 
________________________________
(1)The Company’s principal products include DEFINITY and TechneLite and are categorized within product revenue, net. The Company applies the
same revenue recognition policies and judgments for all of its principal products.
The Company classifies its revenues into three product categories: precision diagnostics, radiopharmaceutical oncology, and strategic partnerships and other. Precision diagnostics includes DEFINITY, TechneLite and other imaging diagnostic products. Radiopharmaceutical oncology consists of AZEDRA and other oncologic therapeutics. Strategic partnerships and other includes partnerships related to other products, such as RELISTOR, that improve patient outcomes and care.
Revenue by product category on a net basis is as follows:
Three Months Ended
March 31,
(in thousands)2021
2020(1)
   DEFINITY$55,971 $52,505 
   TechneLite22,800 22,779 
   Other precision diagnostics6,984 13,057 
Total precision diagnostics85,755 88,341 
Radiopharmaceutical oncology1,500 1,968 
Strategic partnerships and other5,254 395 
   Total revenues$92,509 $90,704 
________________________________
(1)The Company reclassified rebates and allowances of $4.7 million for the three months ended March 31, 2020 within each product category, which included $4.3 million for DEFINITY, $0.3 million for TechneLite and $0.1 million for other precision diagnostics.
The Company’s performance obligations are typically part of contracts that have an original expected duration of one year or less. As such, the Company is not disclosing the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied (or partially satisfied) as of the end of the reporting period.